Corrigenda

Abstract

Alimentary Pharmacology & TherapeuticsVolume 34, Issue 11-12 p. 1357-1357 Free Access Corrigenda This article corrects the following: Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis W. Kruis, L. Jonaitis, J. Pokrotnieks, T. L. Mikhailova, M. Horynski, M. Bátovský, Y. S. Lozynsky, Y. Zakharash, I. Rácz, K. Kull, A. Vcev, M. Faszczyk, K. Dilger, R. Greinwald, R. Mueller, , Volume 33Issue 3Alimentary Pharmacology & Therapeutics pages: 313-322 First Published online: December 8, 2010 First published: 16 November 2011 https://doi.org/10.1111/j.1365-2036.2011.04881.x Dr W. Kruis E-mail: kruis@evkk.de AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat In the paper, ‘Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis’, published in Volume 33 Issue 3 (February 2011), Figure 2a appears incorrectly as Figure 2b and vice versa. All references to these figures and the conclusions drawn from them were correct, and remain so. Please refer to the corrected figures below: (2) [ Primary efficacy endpoint (proportion of patients in clinical remission at final visit, with relapse defined as CAI >4 and ≥3 increase from baseline) according to treatment group for (a) intention-to-treat (ITT) population, *superiority test, 95% CI for difference [−0.026; 0.143]; **superiority test, 95% CI for difference [0.050; 0.225]; ***non-inferiority test, 95% CI for difference [−0.169; 0.011]; and (b) per protocol [PP] population, *superiority test, 95% CI for difference [0.001; 0.160]; **superiority test, 95% CI for difference [0.107; 0.279]; ***non-inferiority test, 95% CI for difference [−0.204, −0.022]. ] The authors apologise for this error. Reference 1 Kruis W, Jonaitis L, Pokrotnieks J, et al. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Aliment Pharmacol Ther 2011; 33: 313– 22. Wiley Online LibraryCASPubMedWeb of Science®Google Scholar Volume34, Issue11-12December 2011Pages 1357-1357 ReferencesRelatedInformation